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Abstract
GRB-associated binding protein 2 (GAB2) represents a compelling genome-wide association signal for late-onset Alzheimer’s
disease (LOAD) with reported odds ratios (ORs) ranging from 0.75–0.85. We tested eight GAB2 variants in four North
American Caucasian case-control series (2,316 LOAD, 2,538 controls) for association with LOAD. Meta-analyses revealed ORs
ranging from (0.61–1.20) with no significant association (all p.0.32). Four variants were hetergeneous across the
populations (all p,0.02) due to a potentially inflated effect size (OR= 0.61–0.66) only observed in the smallest series (702
LOAD, 209 controls). Despite the lack of association in our series, the previously reported protective association for GAB2
remained after meta-analyses of our data with all available previously published series (11,952-22,253 samples; OR = 0.82–
0.88; all p,0.04). Using a freely available database of lymphoblastoid cell lines we found that protective GAB2 variants were
associated with increased GAB2 expression (p = 9.56102729.361026). We next measured GAB2 mRNA levels in 249 brains
and found that decreased neurofibrillary tangle (r =20.34, p = 0.0006) and senile plaque counts (r =20.32, p = 0.001) were
both good predictors of increased GAB2 mRNA levels albeit that sex (r =20.28, p = 0.005) may have been a contributing
factor. In summary, we hypothesise that GAB2 variants that are protective against LOAD in some populations may act
functionally to increase GAB2 mRNA levels (in lymphoblastoid cells) and that increased GAB2 mRNA levels are associated
with significantly decreased LOAD pathology. These findings support the hypothesis that Gab2 may protect neurons
against LOAD but due to significant population heterogeneity, it is still unclear whether this protection is detectable at the
genetic level.
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Introduction
Genome-wide association studies (GWAS) represent an unbi-
ased approach to identify susceptibility loci from complex diseases
such as late-onset Alzheimer’s disease (LOAD). Besides the
consistently reported APOE locus, several strong GWAS signals
(eg. BIN1, CLU, CR1 and PICALM) have recently been identified
[1,2,3] and replicated in independent follow-up studies or GWAS
[4,5,6,7,8,9,10]. As a result, variants at these loci currently (as of
February 2013) show the strongest association with LOAD risk in
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meta-analyses of published studies for all LOAD candidates
performed by the AlzGene forum, available at www.alzgene.org
[11]. Historically, effect sizes and significance levels of many
promising LOAD variants have diminished following publication
of multiple independent case-control association studies, thus
highlighting the importance of more follow-up studies for these
putative variants.
The genetic locus encoding GRB-associated binding protein 2
(GAB2) is an example of a candidate gene that has shown relatively
consistent replication in eleven published studies since its
identification in 2007 [12] and still remains a strong LOAD
candidate [13]. The GAB2 signal was initially identified as a
LOAD candidate in APOE e3e4 carrier and non-carrier subgroups
of a LOAD GWAS [12]; within the discovery subgroup of APOE
e3e4 carriers, 10 of the 25 most significant variants associated with
LOAD were located in GAB2 on chromosome 11q14.1. Combin-
ing data from neuropathological and clinical replication cohorts
revealed highly significant associations of all ten GAB2 variants
(9.7610211,p,1.261025) with LOAD. The numerous follow-up
case-control association studies of GAB2 and subsequent GWAS
have provided further support for GAB2 as a strong candidate
LOAD gene; while only four [14,15,16,17] of the nine studies of
Caucasian European populations [1,5,14,15,16,17,18,19,20] suc-
cessfully replicated the association observed by Reiman et al.,
individually, meta-analyses of all published studies performed by
AlzGene [11] reported significant ORs for all ten GAB2 variants in
the Caucasian studies (most studied variant: rs4945261,
OR=0.79, 95%CI 0.66–0.94). Although the GAB2 variants were
not significantly associated with LOAD in Japanese [21] or Han
Chinese populations [22], addition of these data to the meta-
analysis still revealed a significant pooled odds ratio for all variants
(most studied variant: rs4945261, OR=0.82, 95%CI 0.70–0.95).
Overall, these studies provide good genetic evidence for GAB2 as a
LOAD candidate worthy of further investigation.
Here we have genotyped eight GAB2 variants identified by
Reiman et al in our large, case-control association series (2,316
LOAD and 2,538 controls) in an attempt to replicate and further
strengthen the genetic association of GAB2 with LOAD. In our
previous publication [23], which included case-control association
of the GAB2 variant, rs10793294, we observed significant
population heterogeneity of GAB2 between our case-control series
(p = 0.0002) and between all published series (p,0.0001). Despite
this heterogeneity, meta-analysis of all published studies revealed
significant association of rs10793294 with LOAD (minor allele
OR=0.74, p = 0.007). These findings suggested that either there
was population-specific association of this GAB2 variant such that
the association in some populations is strong enough to withstand
the dilution caused when the data are combined with populations
that show no significant association or that some populations
lacked the necessary statistical power to detect the significant
association. To examine this further we provide statistical tests for
population heterogeneity for all eight variants and meta-analyses
of all available published data for these eight variants analyzing a
total of 11,952-22,253 samples. We have also tested for association
of GAB2 haplotypes with GAB2 mRNA levels using a) a database
made available by Dixon et al [24] and b) post-mortem cerebellum
and temporal cortex samples. Finally, we have tested the GAB2
mRNA levels in temporal cortex and cerebellum for association
with senile plaque and neurofibrillary tangle counts. This study
therefore represents a thorough investigation of GAB2 at the
genetic, transcript and pathological level.
Methods
Ethics Statement
Approval was obtained from the ethics committee or institu-
tional review board of each institution responsible for the
ascertainment and collection of samples (Mayo Clinic College of
Medicine, Jacksonville, FL and Mayo Clinic College of Medicine,
Rochester, MN, USA, National Cell Repository for Alzheimer’s
disease, Indianapolis. IN, USA). Written informed consent was
obtained for all individuals that participated in this study.
Case-control subjects
The case-control series consisted of 4,968 Caucasian subjects
from the United States (2,316 LOAD, 2,538 control) ascertained
at the Mayo Clinic (1,728 LOAD, 2,329 controls) or through the
National Cell Repository for Alzheimer’s Disease (NCRAD: 588
LOAD, 209 control). All subjects ascertained at the Mayo Clinic in
Jacksonville, Florida (JS: 589 LOAD, 593 control) and at the Mayo
Clinic in Rochester, Minnesota (RS: 553 LOAD, 1,374 control)
were diagnosed by a Mayo Clinic neurologist. The neurologist
confirmed a Clinical Dementia Rating score of 0 for all JS and RS
subjects enrolled as controls; cases had diagnoses of possible or
probable LOAD made according to NINCDS-ADRDA criteria
[25]. In the autopsy-confirmed series (AUT: 586 LOAD, 362
control) all brains were evaluated by Dr. Dennis Dickson and
came from the brain bank maintained at the Mayo Clinic in
Jacksonville. The diagnosis of definite AD was made according to
NINCDS-ADRDA criteria. All LOAD brains analyzed in the
Table 1. Details of samples used in this study.
N E4+; N (freq) E4-; N (freq) Females; N(freq) Mean Age (range)
Series LOAD CTRL Total LOAD CTRL LOAD CTRL LOAD CTRL LOAD CTRL
JS 589 593 1,182 367 (0.62) 152 (0.26) 222 (0.38) 441 (0.74) 366 (0.62) 357 (0.60) 78.2 (61-95) 77.9 (60-100)
RS 553 1,374 1,927 309 (0.56) 340 (0.25) 244 (0.48) 1,034 (0.75) 346 (0.63) 747 (0.54) 79.6 (61-104) 78.4 (60-99)
AUT 586 362 948 363 (0.62) 80 (0.22) 223 (0.38) 282 (0.78) 345 (0.59) 154 (0.43) 81.1 (61-105) 75.8 (61-98)
Subtotal 1,728 2,329 4,057 1,039 (0.60) 572 (0.25) 689 (0.40) 1,757 (0.75) 1,057 (0.61) 1,258 (0.54) 79.6 (61-105) 77.9 (60-100)
NCRAD 588 209 797 467 (0.79) 34 (0.16) 121 (0.21) 175 (0.84) 398 (0.68) 129 (0.62) 75.3 (61-98) 78.3 (61-99)
Total 2,316 2,538 4,854 1,498 (0.65) 606 (0.24) 818 (0.35) 1,932 (0.76) 1,455 (0.63) 1,387 (0.55) 78.6 (61-105) 77.9 (60-100)
B) Variant ID, base pair position (BP) on Chromosome 11 (genomic contig reference assembly), genotype counts (11 =major allele homozygote, 12 = heterozygote,
22 =minor allele homozygote) and minor allele frequencies (MAF) are shown for each case-control series and in the total dataset.
The number of LOAD patients (AD) and controls (CTRL), APOE e4 carriers (E4+) and non-carriers (E4–), females and mean age (at diagnosis/entry) are given for each
individual Mayo Clinic series, the Mayo Clinic subtotal, the NCRAD series and the total dataset.
doi:10.1371/journal.pone.0064802.t001
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study had a Braak score of 4.0 or greater. Brains employed as
controls had a Braak score of 2.5 or lower but often had brain
pathology unrelated to AD and pathological diagnoses that
included vascular dementia, fronto-temporal dementia, dementia
with Lewy bodies, corticobasal degeneration, argyrophilic grain
disease, multi-system atrophy, amyotrophic lateral sclerosis, and
progressive supra-nuclear palsy. One LOAD case from each of the
588 late-onset NCRAD families was analyzed. NCRAD LOAD
cases were selected based on strength of diagnosis (autopsy-
confirmed: 38%. probable: 54%. possible: 10%); the case with
the earliest age at diagnosis was taken when several cases had
equally strong diagnoses. The 209 NCRAD controls that we
employed were unrelated Caucasian subjects from the United
States with a Clinical Dementia Rating of 0, specifically collected
for inclusion in case-control series. The number of APOE e4+ and
e4- individuals, females and mean age at diagnosis/entry in the
LOAD cases and controls for each series are shown in Table 1. In
the meta-analyses of all published data, genotype counts were
requested from Harold et al. [1]. These samples were provided by
the Genetic and Environmental Risk for Alzheimer’s disease
(GERAD1) Consortium, comprising 3333 cases and 1225 elderly
screened controls genotyped at the Sanger Institute on the
Illumina 610-quad chip. In this study, we included the UK
samples (recruited by the Medical Research Council (MRC)
Genetic Resource for AD (Cardiff University; Kings College
London; Cambridge University; Trinity College Dublin), the
Alzheimer’s Research Trust (ART) Collaboration (University of
Nottingham; University of Manchester; University of South-
ampton; University of Bristol; Queen’s University Belfast; the
Oxford Project to Investigate Memory and Ageing (OPTIMA),
Oxford University); MRC Prion Unit, University College London;
London and the South East Region AD project (LASER-AD),
University College London; Competence Network of Dementia
(CND) and the German samples (recruited by Department of
Psychiatry, University of Bonn, Germany). The US samples from
the Mayo Clinic were excluded here due to overlap with our
samples. All AD cases met criteria for either probable (NINCDS-
ADRDA, DSM-IV) or definite (CERAD) AD. All elderly controls
were screened for dementia using the MMSE or ADAS-cog, were
determined to be free from dementia at neuropathological
examination or had a Braak score of 2.5 or lower.
DNA isolation
For the JS and RS samples, DNA was isolated from whole blood
using an AutoGen instrument (AutoGen, Inc, Holliston, MA). The
DNA from AUT samples was extracted from cerebellum using
WizardH Genomic DNA Purification Kits (Promega Corp.,
Madison, WI). DNA from the RS and AUT series was scarce,
so samples from these two series were subjected to whole genome
amplification using the Illustra GenomiPhi V2 DNA Amplification
Kit (GE Healthcare Bio-Sciences Corp., Piscataway, NJ).
Genotyping of variants
We genotyped eight of the ten GAB2 variants included in the
Reiman et al. study; rs2510038 was not genotyped since it was not
compatible with our Sequenom genotyping multiplex PCR pool
and rs10793294 was not included in the single variant association
part of this study since we have previously published significant
association of this variant with LOAD [23] but was included in the
latter part of the study. Genotyping of rs10793294 is described in
our previous publication. The remaining eight variants were
genotyped using SEQUENOM’s MassArray iPLEX technology
(SEQUENOM Inc, San Diego, CA) following the manufacturer’s
instructions. Genotype calls were made using the default post-
processing calling parameters in SEQUENOM Typer 4.0
software, followed by visual inspection to remove genotype calls
that were obviously erroneous, based on the presence or absence
of allele peaks in an individual sample spectrogram.
Measurement of GAB2 mRNA Expression
Total RNA was extracted from 356 samples of cerebellum and
163 samples of temporal cortex from LOAD brains and controls
using an ABI PRISM 6100 Nucleic Acid PrepStation and the
Total RNA Isolation Chemistry kit from Applied Biosystems.
RNA was reverse transcribed to single-stranded cDNA using the
High-Capacity cDNA Archive Kit from Applied Biosystems. Real-
time quantitative PCR was performed in triplicate for each sample
using ABI TaqMan Low Density expression Arrays (384-Well
Micro Fluidic Cards) with a pre-validated TaqMan Gene
Expression Assay. 18s ribosomal RNA (18s rRNA) was used as
the endogenous control for the relative quantification of GAB2
mRNA. Real-time PCR cycle threshold (CT) raw data was
collected and exported using the ABI PRISMH SDS software
version 2.2. The variable CT within the raw data file indicates the
PCR cycle number at which the amount of amplified gene target
reaches a fixed threshold. The variable DCT denotes the difference
between the averaged CT values for the GAB2 transcript and that
for the reference 18S rRNA transcript. The DCT values calculated
from each sample were used as quantitative phenotypes to
determine associations between GAB2 haplotypes and the level
of GAB2 transcript. Some samples had one or more replicate
measurements that failed to amplify and were obvious outliers,
thus they were excluded from the analysis.
Pathological measures
Of the postmortem samples, neuropathological data was
available for 128 LOAD patients and 121 controls. Senile plaques
and neurofibrillary tangles were counted in three cortical sections
with thioflavin-S fluorescent microscopy. All neuropathological
assessments were blinded to the medical records. All aspects of the
study were approved by the Mayo Institutional Review Board.
Statistical Analyses
Single variant case-control association study: Breslow-
Day tests and meta-analyses were performed using StatsDirect
v2.5.8 software. Summary ORs and 95% CI were calculated using
the Dersimonian and Laird (1986) random-effects model. Geno-
type counts for published data were taken from the AlzGene
website. In the case of the Reiman et al. data, genotype counts
from the total dataset (and not from the APOE E4+ or E4–
subgroups) were used. In the case of the Logistic regression (allelic
model) correcting for APOE e4 dose (0, 1 or 2 copies of the APOE
e4 allele), sex and age-at-diagnosis were performed using
StatsDirect v2.5.8 software. Haplotype estimation and asso-
Figure 1. Meta-analyses of each variant in our four case-control series and all series published to-date. The total number of LOAD and
controls used for each meta-analysis and Breslow-Day (B–D) p-value for all series are shown at the top of each graph. ORs (boxes) and 95%CI
(whiskers) are plotted for each population and tabulated on the right of each graph. Combined OR is the overall OR calculated by the meta-analysis
using a random effects model. Meta-analysis p-value for all series is shown to the left of the combined odds ratio. Breslow-Day and Meta-analysis p-
values for our data only are shown next to the OR plots for JS, RS, AUT and NCRAD series.
doi:10.1371/journal.pone.0064802.g001
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ciation study: Haplotype frequencies were estimated using the
expectation-maximization approach implemented in the haplo.em
function of Haplo.stats v1.2.2 [26] using R programming software.
Global haplotype association and individual haplotype score tests
corrected for APOE e4 dose, sex and age-at-diagnosis were
performed using the haplo.score function of Haplo.stats v1.2.2.
Conserved region search: A search was performed for .70%
identity (the default parameter for defining a conserved element
[27]) over 100 bp windows between the human (Human April
2003 genome build) and mouse (February 2003 build) sequence as
determined by the pre-computed alignments in the VISTA
Genome Browser (http://pipeline.lbl.gov/cgi-bin/gateway2). Ep-
istatic Interaction: All nine GAB2 variants and the two variants
in APOE that confer allelic status (rs7412 and rs429358) were
tested for pair-wise epistatic interaction using the –epistasis
function of PLINK v1.07 (http://pngu.mgh.harvard.edu/
purcell/plink/) [28]. Covariates could not be included in these
analyses due to software limitations. Association of GAB2
mRNA levels (DCT) with covariates and pathological
traits: Spearman correlations, chi-squared and independent t-
tests were performed in StatsDirect v2.5.8 software. Age-at-death,
neurofibrillary tangle counts and senile plaque counts were
included as continuous traits, while APOE e4 dose (0, 1, 2) and
sex were included as categorical traits.
Results
No association of GAB2 variants with LOAD risk in 2,316
LOAD patients and 2,538 controls from North America
We genotyped eight GAB2 variants in our large case-control
dataset (Table 1) that includes 2,316 LOAD patients and 2,538
controls of North American Caucasian descent. Table 2 shows the
genotype counts for these eight variants in each series. All variants
were in Hardy-Weinberg equilibrium (all p.0.1). As shown in
Figure 1, meta-analyses of our four case-control series (JS, RS,
AUT, NCRAD) revealed no association overall for any of the eight
variants with LOAD risk (all Meta p.0.3) albeit that five variants
were associated with LOAD in the NCRAD series; rs1385600
(OR=0.64, 95%CI 0.48–0.86), rs1007837 (OR=0.61, 95%CI
0.46–1.81), rs4291702 (OR=0.65, 95%CI 0.49–0.87), rs7115850
(OR=0.66, 95%CI 0.50–0.88) and rs2373115 (OR=0.72,
95%CI 0.54–0.97). Population heterogeneity for the four variants
(Breslow-Day p-values; rs1385600 p= 0.01, rs1007837 p=0.006,
rs4291702 p= 0.02, rs7115850 p=0.02) disappeared when the
NCRAD series was removed from the analysis (all p.0.11; data
not shown). It must be noted that NCRAD was the smallest of the
four case-control series, suggesting the possibility that the
increased frequency observed in the 209 controls could in fact
be an artefact. Nevertheless, the protective associations for the
minor allele of these five variants in the NCRAD series successfully
replicate the risk associations reported for the major alleles of the
same variants reported in the Reiman et al study. In order to
further evaluate the association in the NCRAD series and to
determine whether they were independent of covariates, we
performed logistic regression for all eight variants correcting for
APOE e4 dose (0, 1 or 2 copies of the APOE e4 allele), sex and age-
at-diagnosis/sampling in the NCRAD series (Table 3). Effect sizes
for these five associations did not remain following adjustment for
covariates (all p.0.09) indicating that the associations were not
independent associations.
Since Reiman et al observed stronger associations in their APOE
e4+ subgroup, we also show the genotype counts (Table S1) and
association results (Table 3) for the NCRAD APOE e4+ and e4–
negative subgroups respectively. As shown in Table 3, unlike theT
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associations reported by Reiman et al., there was no association
with LOAD in the e4+ or e4– individuals (all p.0.06). We also
tested for association of these eight variants in the APOE e4
subgroups for our other case-controls series (JS, RS and AUT),
however these data revealed no significant association (all p.0.05;
data not shown).
The GAB2 locus shows significant heterogeneity across
populations in a meta-analysis of 12,000+ samples
We next added our data to the available published data (ranging
from 11,952 to 22,253 samples) to determine whether the
significant association reported on Alzgene (www.alzgene.org)
would survive the addition of 4,854 samples (22–40% increase in
sample size), that showed no association individually). As shown in
Figure 1, despite significant population heterogeneity across the
series for all variants (all p,0.007), the GAB2 association with
LOAD remained for all variants using the combined random
effects model (all p,0.04).
Association of GAB2 variants with LOAD is dependent
upon on haplotypic background
The comparable frequency (13.3%–20.9%) and effect size
(OR=0.79–0.88) that we report for the GAB2 variants are likely
due to the substantial linkage disequilibrium within the GAB2
region (all pair-wise r2 .0.91). In order to characterize further the
association of GAB2 variants with LOAD, haplotypes were
constructed for the eight variants as well as rs10793294 for which
we had genotype data available (Table 4). These nine variants,
spanning 161 kb of GAB2 (202 kb), comprised three haplotypes
with a frequency .1% in the RS, JS and AUT series and four
haplotypes in the NCRAD series. This additional low frequency
haplotype in the NCRAD series further highlights the heteroge-
neity that we observed for those samples in the single variant
analyses.
We performed global tests for haplotypic association with
LOAD risk in each case-control series thereby reducing the
number of tests performed. The haplotype frequencies and global
haplotype p-values for each series are shown in Table 4.
Consistent with the single variant results, the only series to show
association was NCRAD (Global p-value = 0.0001). Individual
haplotype score tests were subsequently calculated for NCRAD
revealing that the most common haplotype (H1), which comprised
the major allele at all nine variants, was present at an increased
frequency in LOAD (79.8%, n= 1096) compared to control
(69.0%, n= 280) chromosomes (OR=1.86, p = 7.9361025). This
is comparable to the findings reported by Reiman et al in their
APOE e4+ series (Discovery cohort; 76% LOAD, 68% controls,
OR=1.39, p = 0.05). Reflecting the strong linkage disequilibrium
in this region, the second most common haplotype (H2) is
comprised of the minor allele at all nine variants. Although a trend
towards an opposing effect compared to H1 was observed
(OR=0.84), the association was not significant (p = 0.39). The
third haplotype (H3) comprised the same alleles as H1 with the
exception of rs10793294, for which we have previously published
a significant protective association with LOAD [23]. Consistent
with these previous findings, possession of rs10793294 on the H1
background resulted in a trend towards decreased risk (OR=0.58,
p = 0.07) compared to the risk association of H1 (OR=1.86).
The haplotype frequencies observed here and the lack of
association of H2 and H3 with LOAD are comparable to the
findings of Reiman et al. In addition, we also observed a novel
observation in the NCRAD series where a fourth haplotype (H4)
was present at an increased frequency in controls (3.2%) compared
to the other series such that it surpassed the 1% frequency cut-off
for analysis. This haplotype, present in 8 (0.6%) LOAD compared
to 13 (3.2%) control chromosomes, was associated with decreased
risk for LOAD (OR=0.17, p= 0.003), consistent with the fact that
it comprises the five protective alleles observed in the single variant
tests (Figure 1) as well as the protective rs10793294 allele [23].
Since Reiman et al used a haplotype frequency cut-off .5% they
did not include this relatively rare haplotype in their analyses and
so we are unable to ascertain whether the control samples in that
study also had an increased frequency of this haplotype as
observed in the NCRAD series. Since H4 was the only protective
haplotype in these data (p,0.05), these findings indicate that a
complex interaction of multiple functional variants across GAB2
haplotypes is required to confer protection against LOAD rather
than possession of any single GAB2 variant. Notably, a search for
conserved sequence revealed that rs901104 (71%), rs7115850
(95%) and rs2373115 (90%) lay in regions .70% conserved
between human and mouse genomes making these three variants
strong candidates for functional studies.
Table 3. Single variant association of eight GAB2 variants with LOAD in the NCRAD series.
Variant Min Allele NCRAD e4+/– NCRAD e4+ NCRAD e4–
OR 95% CI p OR 95% CI p OR 95% CI p
rs901104 A 0.86 0.59–1.26 0.44 1.06 0.64–1.76 0.81 0.73 0.45–1.18 0.20
rs1385600 G 0.79 0.58–1.08 0.14 0.60 0.33–1.12 0.11 0.84 0.60–1.16 0.28
rs1007837 C 0.76 0.56–1.05 0.09 0.60 0.33–1.10 0.10 0.81 0.57–1.13 0.21
rs4945261 A 0.96 0.74–1.25 0.78 0.97 0.59–1.58 0.90 0.95 0.69–1.30 0.74
rs7101429 G 0.96* 0.74–1.25 0.76 0.96* 0.59–1.58 0.89 0.95* 0.69–1.30 0.74
rs4291702 T 0.78 0.57–1.06 0.12 0.57 0.31–1.03 0.06 0.84 0.61–1.16 0.29
rs7115850 C 0.82 0.61–1.10 0.18 0.64 0.35–1.17 0.15 0.86 0.62–1.18 0.34
rs2373115 A 1.03 0.87–1.22 0.72 0.83 0.47–1.45 0.51 1.08 0.88–1.33 0.48
OR; odds ratio, 95%CI; 95% confidence intervals for binary logistic regression adjusted for APOE e4 dose, sex and age-at-diagnosis.
*Schjeide et al published association of rs7101429, with LOAD in samples obtained from NCRAD [34]; although we have no way of ascertaining the level of sample
overlap between these studies the different ORs reported in that publication (e4+/–; 0.70, e4+; 0.70, e4–; 0.74) suggests our study contains some novel samples.
doi:10.1371/journal.pone.0064802.t003
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Epistatic interaction exists between GAB2 and APOE
variants
In order to determine whether any genetic interaction exists
between the GAB2 and other strong LOAD candidates to modify
LOAD risk, we tested for pair-wise epistatic interaction between
the nine GAB2 variants studied here and the strongest known
LOAD risk factor, APOE e4, as well as the top GWAS-identified
variants for which we had genotype information available; BIN1
(rs744373), CLU (rs11136000), CR1 (rs3818361) and PICALM
(rs3851179). The results for all 105 tests performed for each of the
interactions are shown in Table S2. While we report 17
interactions (all APOE-APOE, GAB2-GAB2 or GAB2-APOE) at the
p#0.05 level (Table 5), the only interaction that would survive
Bonferroni correction for the 105 tests performed (p,0.0005) is
the interaction between the two APOE variants that confer ApoE
allelic status (p = 4.1610212). Four GAB2-APOE interactions
surpassed the p,0.05 cut-off; APOE rs7412 6 AB2 rs10793294
(p = 0.016), rs1008737 (p = 0.026), rs7115850 (p= 0.045),
rs4291702 (p= 0.049). Due to the multiple testing inherent in
these analyses, further investigation of these possible epistatic
interactions in multiple, independent studies is required in order to
determine whether there is true synergy between the variants.
Protective GAB2 variants are associated with increased
GAB2 mRNA levels in lymphoblastoid cell lines
In an attempt to identify whether any of these GAB2 variants
could be associated with altered GAB2 expression, we performed
an in silico search of the data published by Dixon et al [24] in which
they genotyped 498,273 variants across the human genome and
measured quantitative expression of 54,675 transcripts represent-
ing 20,599 genes in Epstein-Barr virus-transformed lymphoblas-
toid cell lines (LCLs) derived from peripheral blood lymphocytes
taken from 400 children. As shown in Table 6, although only three
(rs1385600, rs4945261 and rs2373115) of the nine GAB2 variants
described here were included on the two genotyping platforms
used by Dixon et al, all three were associated (p = 9.561027,
9.361026 and 9.361026 respectively) with one of the six GAB2
expression probes tested (1566958_at). Data pertaining to the
association of these variants with the other five GAB2 probes was
not available indicating that the association fell below the cut-off
LOD score (LOD.2) for inclusion in the database. The negative
effect sizes shown in Table 6 indicate decreased GAB2 expression
associated with the major allele or inversely, increased GAB2
expression associated with the minor allele in LCLs. Notably, the
minor allele of all three of these variants were associated with
decreased risk for LOAD in our NCRAD series. Therefore,
variants associated with increased GAB2 transcript (in LCLs) are
also associated with decreased risk for LOAD.
In order to determine whether the variants were associated with
altered GAB2 expression in a tissue more directly relevant to
LOAD, we measured GAB2 mRNA levels in 356 cerebellum
samples and 163 temporal cortex samples obtained from our
autopsy-confirmed series (AUT) of LOAD patients and controls.
DCT GAB2 levels measured for all samples are available in Table
S3. To decrease the number of statistical tests performed we tested
for global association of the GAB2 haplotypes with GAB2 mRNA
levels (one test) rather than testing each individual variant (9 tests).
As shown in Table 7 we observed no global haplotypic association
with GAB2 mRNA levels in either temporal cortex or cerebellum
regions in the LOAD patients or controls or when the two groups
were pooled (all global p.0.43). Therefore, these data from the
cerebellum and temporal cortex of LOAD patients (mean
age = 74) and controls (mean age = 72) did not replicate the
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association of protective GAB2 variants with increased GAB2
transcript levels observed in the peripheral blood lymphocytes of
children.
Increased GAB2 mRNA levels in the postmortem
temporal cortex are associated with decreased AD
pathology
We next assessed whether GAB2 was differentially expressed in
the postmortem temporal cortex and cerebellum samples from
LOAD and control patients. The number of pathologial markers
(cortical neurofibrillary tangles and senile plaques) counted for
each sample is shown in Table S3. As shown in Table 8, while
GAB2 mRNA levels did not significantly differ between LOAD
and control brains in the cerebellum (two-tailed p= 0.26),
increased GAB2 mRNA levels were measured in the temporal
cortex of control versus LOAD brains (two-tailed p= 0.0006)
suggesting the possibility that increased GAB2 expression could be
protective against (or down-regulated in response to) LOAD.
Alternatively, it is possible that GAB2 mRNA expression is acting
as a proxy for another confounding variable. To investigate this,
we tested for differences in RNA integrity (RNA integrity number
or RIN), age-at-death, APOE e4 dose and sex between LOAD and
control samples (Table 8). We found no difference in RIN
(cerebellum one-sided p= 0.59; temporal cortex one-sided
p= 0.89) thereby demonstrating that the integrity of the RNA
was not affected by the presence of AD pathology. We did
however find that the LOAD brains on average were taken from
older individuals (mean age difference = 2.2 years; p = 0.002) from
a greater number of APOE e4 carriers (36% more versus controls;
p,0.0001) and a greater number of females (15% more versus
controls; p = 0.02).
We next tested for a correlation between GAB2 mRNA levels
and RIN, age-at-death, APOE e4 dose, sex and postmortem
pathology. To increase the statistical power we tested for
association in all post-mortem brains (LOAD and controls). As
shown in Table 9, we found that RIN (r = 0.68, p,0.0001), sex
(r =20.28, p = 0.005), number of NFTs (r =20.34, p = 0.0006)
and number of senile plaques (r =20.32, p = 0.001) were the best
predictors of GAB2 mRNA levels in the temporal cortex whereas
RIN (r = 0.76, p,0.0001) was the best predictor in cerebellum (a
brain region much less affected by AD pathology than the cortex).
Although the NFT and senile plaque counts were strongly
correlated with each other (r = 0.84, p,0.0001), neither were
correlated with RIN for RNA extracted from the temporal cortex
(r =20.06, p= 0.29 and r =20.05, p= 0.31, respectively) indicat-
ing that the correlation of plaque and tangle count with cortical
GAB2 levels cannot be attributed to by increased RNA integrity of
samples with less pathology. On the other hand the NFT (r = 0.20,
Table 5. Pair-wise epistatic interaction tests between variants in GAB2 and APOE.
Variant 1 Variant 2 Interaction
Chr Gene Variant Chr Gene Variant OR Chi2 p-value
19 APOE rs429358 19 APOE rs7412 1.96 48.09 4.1610212
11 GAB2 rs1007837* 11 GAB2 rs2373115* 1.32 6.99 0.008
11 GAB2 rs1385600* 11 GAB2 rs1007837* 1.30 6.03 0.014
11 GAB2 rs10793294 19 APOE rs7412 0.85 5.85 0.016
11 GAB2 rs1007837* 19 APOE rs7412 0.85 4.93 0.026
11 GAB2 rs1007837* 11 GAB2 rs7101429 1.28 4.87 0.027
11 GAB2 rs1007837* 11 GAB2 rs7115850* 1.25 4.80 0.028
11 GAB2 rs1007837* 11 GAB2 rs4945261 1.27 4.76 0.029
11 GAB2 rs1385600* 11 GAB2 rs2373115* 1.25 4.62 0.032
11 GAB2 rs901104 11 GAB2 rs1007837* 1.26 4.29 0.038
11 GAB2 rs1385600* 11 GAB2 rs7101429 1.25 4.19 0.041
11 GAB2 rs1385600* 11 GAB2 rs7115850* 1.23 4.19 0.041
11 GAB2 rs1385600* 11 GAB2 rs4945261 1.25 4.07 0.044
11 GAB2 rs7115850* 19 APOE rs7412 0.86 4.02 0.045
11 GAB2 rs4291702* 11 GAB2 rs2373115* 1.23 4.01 0.045
11 GAB2 rs1007837* 11 GAB2 rs4291702* 1.23 3.97 0.046
11 GAB2 rs4291702* 19 APOE rs7412 0.86 3.88 0.049
Pair-wise interactions between fifteen variants in GAB2, APOE, BIN1, CLU, CR1 and PICALM (105 tests) were performed. Interactions that gave a p-value ,0.05 are shown
in the table. The chromosome (Chr), gene and variant rs number for each interaction are given under the headings ‘‘Variant 1’’ and ‘‘Variant 2’’. The odds ratio (OR), Chi2
value and p-value for the interaction test are shown for each pair-wise test. *associated with decreased risk in the NCRAD series.
doi:10.1371/journal.pone.0064802.t005
Table 6. GAB2 variants are associated with GAB2 mRNA
expression in lymphoblastoid cells.
ProbeID Variant Allele Effect LOD p-value
1566958_at rs1385600 Maj 20.444 5.218 9.561027
1566958_at rs4945261 Maj 20.451 4.266 9.361026
1566958_at rs2373115 Maj 20.442 5.145 1.161026
Data obtained from database published by Dixon et al.
ProbeID; GAB2 cRNA probe ID (Affymetrix),
Allele; Major allele was tested in this analysis;
Effect; coefficient for linear regression model;
LOD; Logarithm of odds (threshold for genome-wide significance .6.076,
equivalent to p,0.05).
doi:10.1371/journal.pone.0064802.t006
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p= 0.0009) and senile plaque counts (r = 0.19, p = 0.001) were
higher in female brains thus indicating that sex maybe a
contributing factor to the association of increased NFT and senile
plaque counts with decreased cortical GAB2 levels.
Discussion
Successful replication of candidate genes for complex diseases in
multiple, large, independent case-control series are invaluable for
determining true risk loci from false-positive associations. Once
genetic involvement in the disease has been well established,
functional studies can then be used to assess the biochemical
properties of the protein with the aim of identifying putative
therapeutic targets. Here, we have performed a large follow-up
case-control association study for GAB2 and revealed significant
association in one out of the four populations studied for five GAB2
variants (0.0008,p,0.04). However, this positive association must
be treated with caution due to the heterogeneity observed
compared to the other three homogenous populations studied.
The reason for the disparate association in the NCRAD series
could be due to the fact that it is the population with the fewest
controls and therefore more susceptible to inflated effect sizes,
population substructure or genotyping error. Nevertheless, similar
frequencies were also reported to Reiman et al., highlighting the
possibility that there is true population heterogeneity at this locus.
Based on the fact that meta-analysis of the four populations did not
reveal association of any of the variants we can only conclude that
our data do not support the genetic association of GAB2 with
LOAD. As a testament to the increased statistical power achieved
by analyzing multiple, independent case-control series, meta-
analyses for the GAB2 variants combining our data with all
available previously published data (ranging from 11,952 to
22,253 samples) revealed significant association for all nine
variants (all p,0.04) despite significant population heterogeneity
and the fact that 22240% of the samples did not show association
when tested independently.
Investigation of the haplotypic association of GAB2 with LOAD
risk revealed that the relatively rare H4 haplotype (which
comprises the five variants that conferred protection against
LOAD in our NCRAD series and a protective variant we have
reported previously) was observed at an increased frequency in
NCRAD controls (3.2%) compared to NCRAD LOAD patients
(0.6%) and also compared to other control populations (,1%)
indicating that inheritance of these six protective alleles together is
usually rare but when it does occur, it may protect against LOAD.
The fact that H2, a more frequent haplotype (13% LOAD, 14.3%
controls) also comprises the minor allele at these six variants (in
addition to the minor alleles at the other three) but only trends
towards a protective association in the same population (p= 0.39)
suggests that the protection associated with H4 in the NCRAD
Table 7. GAB2 haplotypes are not associated with GAB2 mRNA expression in post-mortem brains.
Brain Region Diagnosis N Global p-value Haplotype (freq)
Temporal Cortex LOAD 85 0.85 H1 (0.80), H2 (0.11), H3 (0.03), H5 (0.01), H4 (0.01)
Temporal Cortex CTRL 78 0.85 H1 (0.80), H2 (0.11), H3 (0.03), H5 (0.01), H4 (0.01)
Temporal Cortex ALL 163 0.67 H1 (0.80), H2 (0.11), H3 (0.04), H4 (0.01)
Cerebellum LOAD 189 0.43 H1 (0.78), H2 (0.15), H3 (0.03), H4 (0.008)*
Cerebellum CTRL 167 0.52 H1 (0.78), H2 (0.13), H3 (0.05), H5 (0.02), H4 (0.009)*
Cerebellum ALL 356 0.46 H1 (0.78), H2 (0.14), H3 (0.04), H5 (0.01), H4 (0.008)*
N; number of individuals included in the analysis.
Global p-value; global association of GAB2 haplotypes with GAB2 mRNA expression in post-mortem temporal cortex and cerebellum samples.
A novel haplotype (H5) comprising the major allele at all variants except rs7115850 and rs2373115 exceeded the cut-off frequency and was observed at a higher
frequency than H4 in four of these sample subgroups.
*Due to the haplotype frequency cut-off (.1%) used in this study H4 was not included in the global analysis for these subgroups.
doi:10.1371/journal.pone.0064802.t007
Table 8. GAB2 mRNA expression is increased in temporal cortex of control compared to LOAD brains.
Variable LOAD (n=128) CTRLs (n =121) LOAD + CTRLs (n=249) p-value
GAB2 mRNA Cerebellum N=127;Mean = 1.7+/20.1 N= 118;Mean = 1.8;+/20.1 N = 245;Mean = 1.7+/20.1 0.26
GAB2 mRNA Temporal cortex N = 59;Mean= 0.8+/20.1 N= 43;Mean = 1.3;+/20.1 N = 102;Mean = 1.0+/20.1 0.0006
RIN Cerebellum N=127;Mean = 7.2+/20.1 N= 118;Mean = 7.1+/20.1 N = 245;Mean = 7.2+/20.1 0.59
RIN Temporal Cortex N = 59;Mean= 6.8+/20.1 N= 43;Mean = 6.8+/20.1 N = 102;Mean = 6.8+/20.1 0.89
Age-at-death (yrs) N = 128;Mean = 73.9+/20.5 N= 121;Mean = 71.7+/20.5 N = 249;Mean = 72.8+/20.3 0.002
APOE 4 (n for 0,1,2 copies) N = 126;(52,58,16) N= 119;(92,26,1) N = 249;(148,84,17) ,0.0001
Sex (M,F) N = 128;(62,66) N= 121;(77,44) N = 249;(139,110) 0.02
Neurofibrillary tangles N = 128;Mean = 11.7+/20.5 N= 121;Mean = 0.1+/20.1 N = 249;Mean = 6.1+/20.5 ,0.0001
Senile plaques N = 128;Mean = 42.9+/20.5 N= 121;Mean = 6.3+/20.9 N = 249;Mean = 25.1+/21.3 ,0.0001
N; number of brains analysed,
Mean; mean value +/2 standard deviation.
p-value; for independent t-test or chi-squared test (APOE e4 dose and sex) for variable in LOAD versus control brains.
doi:10.1371/journal.pone.0064802.t008
Variant GAB2 Expression and Alzheimer Pathology
PLOS ONE | www.plosone.org 9 May 2013 | Volume 8 | Issue 5 | e64802
series is not merely due to possession of the minor allele at these six
variants (present in H2 and H4) but also to the major allele at the
other three (H4). In contrast, lacking the protective alleles (as is the
case in the most common haplotpye, H1), appears to be sufficient
to confer risk for LOAD despite possession of the major alleles at
the other three variants (H1 and H4). These findings provide
support for the hypothesis that susceptibility to LOAD is
dependent on the GAB2 haplotypic background rather than to
possession of a single functional allele. We have identified two of
these protective variants (rs7115850, rs2373115) worthy of
prioritized follow-up functional investigation based on their
location within conserved regions between human and mouse
genomes. It must be noted that according to Tagger (a
bioinformatic tool for the selection and evaluation of tag SNPs
from genotype data [29]), the nine variants analysed here belong
to three of the seven linkage blocks that comprise GAB2. It is
therefore possible that other haplotypes at the GAB2 locus that
were not covered by the variants in this study also contribute to
LOAD risk.
Here we have also shown that all three GAB2 variants included
in a dataset published by Dixon et al were associated with increased
GAB2 mRNA levels in LCLs derived from lymphocytes taken from
children (all p,9.361026); two of these variants were protective in
our NCRAD series. In summary, variants that conferred
protection for LOAD in our NCRAD series and in meta-analysis
of all published data were associated with increased GAB2 mRNA
levels in LCLs, indicating that increased GAB2 levels may be
protective against LOAD.
We next tested for association of GAB2 variants with GAB2
mRNA levels brain tissue obtained at autopsy to improve
detection of LOAD-related GAB2 variant/transcript associations
that might go undetected in the peripheral tissue lymphoblastoid
cell lines. We analysed brain tissue from the temporal cortex, the
most affected brain region in LOAD but because LOAD causes
profound neuronal cell loss and astrogliosis that will alter mRNA
levels in affected regions, mRNAs were also measured in the
cerebellum which is largely unaffected by LOAD pathology.
Although the single variants trended towards the same association
observed in the LCLs we did not observe any significant
association in postmortem cerebellum or temporal cortex samples
from control and LOAD brains. One possible explanation for this
is that mRNAs are degraded in the postmortem interval and are
likely to be influenced by the agonal state prior to death, which
could alter the GAB2 transcript level. The Dixon et al study
measured GAB2 transcript levels in lymphocytes taken from living
children and so would have been unaffected by the agonal state.
Overall, there are many possible explanations for the lack of
replication observed between LCLs and postmortem samples that
include but are not limited to the lack of power to detect the
association in postmortem tissue, tissue-specific, age-related or
disease-specific expression levels of GAB2 mRNA.
The assertion that increased GAB2 expression levels may protect
against LOAD is not novel. Other studies have shown that Gab2
protein is detected in AD brains with the highest levels found in
some of the most affected AD areas such as the hippocampus and
cingulate gyrus within highly dystrophic neurons containing
neurofibrillary tangles, which along with senile plaques, are a
pathological hallmark of AD [12]. Furthermore, Reiman et al
showed that GAB2 siRNA treatment was associated with a 1.70-
fold increase in hyper-phosphorylated tau, the principal compo-
nent of neurofibrillary tangles [12]. Based on this finding and
along with the fact that Gab2 is the principal activator of the
phosphatidylinositol 3-kinase signaling pathway [30], activation of
which suppresses glycogen synthase kinase 3-mediated phosphor-
ylation of tau and prevents apoptosis of confluent cells [31],
Reiman et al hypothesized that Gab2 might function to protect
neurons from neurofibrillary tangle formation and that a loss-of-
function GAB2 haplotype would increase tau phosphorylation at
sites abnormally phosphorylated in AD brains. Consistent with this
hypothesis, we have observed a correlation between increased
GAB2 mRNA levels in postmortem temporal cortex and decreased
neurofibrillary tangle counts (p = 0.0006) and decreased senile
plaque counts (p = 0.001). No association was observed in the
cerebellum. Since the temporal cortex is more affected by AD
pathology than the cerebellum it is reasonable to assume that due
to regional specific cell death, the underlying distribution of cells
would be different between the two areas, which could explain
why we see less GAB2 expression in the cortex (mean DCT =1.0)
versus the cerebellum (mean DCT =1.7) and why we see an
association of GAB2 expression with AD pathology in the
predominantly pathology-affected area only. Taken together with
our observation that GAB2 variants associated with decreased risk
for LOAD may increase GAB2 mRNA levels (data taken from
LCLs not the cortex), the correlation of increased GAB2 mRNA
with decreased NFT and senile plaque counts in a tissue directly
affected by LOAD provides further support for the hypothesis that
Gab2 may protect neurons from LOAD pathology.
In summary, we have used a joint analysis approach to identify
biologically congruent associations between genetic association
and gene expression levels. We have identified a strong association
of GAB2 gene expression levels with neurofibrillary tangle and
senile plaque counts in temporal cortex using only 102 subjects
and shown that despite the fact that three of our four case-control
series did not replicate the previously reported evidence that GAB2
Table 9. Increased GAB2 mRNA expression is associated with decreased AD pathology in temporal cortex.
Temporal cortex (n =102) Cerebellum (n=245)
Variable Co-efficient 95% CI p-value Co-efficient 95% CI p-value
RNA integrity number 0.675 0.55 0.77 ,0.0001 0.756 0.69 0.81 ,0.0001
Age-at-death (yrs) 20.078 20.27 0.12 0.43 20.093 20.22 0.04 0.15
APOE 4 dose (0,1,2 copies) 20.084 20.28 0.12 0.40 20.077 20.20 0.05 0.23
Sex (M,F) 20.275 20.45 20.08 0.005 20.115 20.24 0.01 0.07
Number of Neurofibrillary tangles 20.336 20.50 20.15 0.0006 20.071 20.19 0.06 0.27
Number of Senile plaques 20.321 20.49 20.13 0.001 20.097 20.22 0.03 0.13
Co-efficient; Spearman’s rank correlation coefficient, 95%CI; confidence intervals for correlation coefficient, p-value; significance level.
doi:10.1371/journal.pone.0064802.t009
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variants protect against LOAD, our meta-analyses of 11,952-
22,253 samples from this study and those published still showed a
strong association at this locus. Finally we have provided evidence
that these protective variants may functionally increase GAB2 gene
expression. We recently used a similar approach to identify
functional variants in the insulin degrading enzyme that conferred
protection against LOAD [32,33] thus providing further support
for multi-platform approaches to investigate candidate genes for
complex diseases such as LOAD.
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